

**Table S3.** Clinical and laboratory characteristics depending on atrial fibrillation type (in patients with left atrial thrombus, derivation cohort).

Variable	Patients with LAA thrombus (n=59)			p
	Patients with paroxysmal AF (n=10)	Patients with persistent AF (n=36)	Patients with permanent AF (n=13)	
Age [years]	63 (60-69)	65 (58-73)	74 (72-75)	0.06
Female [n (%)]	7 (70%)	10 (28%)	4 (31%)	0.05
BMI [kg/m <sup>2</sup> ]	29 (28-33) <i>n=10</i>	29 (25-31) <i>n=24</i>	34 (24-44) <i>n=3</i>	0.06
Type of procedure planned [n (%)]				
Cardioversion	0 (0%)	7 (19%)	1 (8%)	0.42
Ablation	10 (100%)	29 (81%)	12 (92%)	0.42
Concomitant diseases [n (%)]				
Hypertension	6 (60%)	24 (67%)	8 (62%)	0.86
Dyslipidemia	3 (30%)	13 (36%)	2 (15%)	0.48
Diabetes	3 (30%)	11 (31%)	4 (31%)	1.00
Coronary artery disease	0 (0%)	9 (25%)	5 (39%)	0.09
Previous myocardial infarction	0 (0%)	7 (19%)	2 (15%)	0.45
Peripheral artery disease	0 (0%)	0 (0%)	1 (7.7%)	0.39
Vascular disease (CAD and/or PAD)	0 (0%)	9 (25%)	5 (39%)	0.09
Heart failure	2 (20%)	14 (39%)	8 (62%)	0.16
Previous ischemic stroke/TIA/embolism	0 (0%)	4 (11%)	5 (39%)	0.02

Previous peripheral embolism	0 (0%)	1 (2.8%)	1 (7.7%)	0.62
Biological valve prosthesis	1 (10%)	0 (0%)	1 (7.7%)	0.15
Mechanical valve prosthesis	0 (0%)	1 (2.8%)	0 (0%)	1.00
Chronic respiratory disease	2 (20%)	4 (11%)	1 (7.7%)	0.72
Liver disease	0 (0%)	1 (2.8%)	0 (0%)	1.00
Hyperthyroidism	1 (10%)	2 (5.6%)	3 (23%)	0.12
Hypothyroidism	1 (10%)	2 (5.6%)	1 (7.7%)	0.80
Malignancy	0 (0%)	2 (5.6%)	2 (15%)	0.33
Hyperuricemia	1 (10%)	0 (0%)	1 (7.7%)	0.15
Smoking	3 (30%)	12 (33%)	4 (31%)	0.72
<b>Thromboembolic risk</b>				
CHADS <sub>2</sub> score	2 (2-3)	2 (2-3)	3 (3-4)	<b>0.03</b>
CHA <sub>2</sub> DS <sub>2</sub> -VASc score	2 (2-3)	2 (1-4)	3 (3-4)	0.06
CHA <sub>2</sub> DS <sub>2</sub> -VASc score [n (%)]				
= 0	0 (0%)	1 (2.8%)	0 (0%)	0.09
= 1	2 (20%)	11 (31%)	0 (0%)	0.09
≥ 2	8 (80%)	24 (67%)	13 (100%)	0.09
<b>Antithrombotic treatment [n (%)]</b>				
No OAC	1 (10%)	2 (6%)	3 (23%)	0.60
VKA	8 (80%)	17 (47%)	5 (38.5%)	0.13
NOAC	1 (10%)	17 (47%)	5 (38.5%)	0.11
- dabigatran	0 (0%)	13 (36%)	0 (0%)	<b>0.003</b>
- rivaroxaban	1 (10%)	4 (11%)	5 (38.5%)	0.09
- apixaban	0 (0%)	0 (0%)	0 (0%)	1.00
Antiplatelets	1 (10%)	1 (2.8%)	0 (0%)	0.36
<b>Laboratory parameters</b>				
Hemoglobin [g/dL]	14 (14-15)	14 (13-16)	13 (12-13)	<b>0.001</b>

WBC [K/ $\mu$ L]	8.6 (7.7-9.4)	7.6 (6.5-9.8)	6.5 (6.0-7.1)	0.07
Platelet count [K/ $\mu$ L]	232 (216-321)	213 (165-258)	148 (142-175)	0.0006
GFR [mL/min/1.73 m <sup>2</sup> ]	62 (52-71)	56 (47-81)	56 (33-76)	0.64
<b>Transthoracic echocardiography*</b>				
Ejection fraction [%]	51 (50-52) <i>n=2</i>	54.5 (40-60) <i>n=6</i>	60 (49-64) <i>n=3</i>	0.67
Left atrial diameter [cm]	4.5 (4.4-4.5) <i>n=2</i>	4.9 (4.5-5.2) <i>n=9</i>	4.8 (4.1-5.2) <i>n=3</i>	0.56
<b>Transesophageal echocardiography*</b>				
LAA emptying velocity [cm/s]	23 (18-27)	23 (20-29)	20 (18-20)	0.28
Dense SEC [n (%)]	3 (30%)	11 (31%)	3 (23%)	0.92
SEC [n (%)]	5 (50%)	17 (47%)	8 (62%)	0.71

\* performed during index hospitalization

AF - atrial fibrillation, BMI - body mass index, CAD - coronary artery disease, GFR - glomerular filtration rate, LAA - left atrial appendage, NOAC - non-vitamin K antagonist oral anticoagulants, PAD - peripheral artery disease, SEC - spontaneous echo contrast, TIA - transient ischemic attack, VKA - vitamin K antagonists, WBC - white blood cells